Oppenheimer & Co. Inc. Sells 6,935 Shares of Agilent Technologies, Inc. (NYSE:A)

Oppenheimer & Co. Inc. trimmed its stake in Agilent Technologies, Inc. (NYSE:AFree Report) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,644 shares of the medical research company’s stock after selling 6,935 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Agilent Technologies were worth $1,480,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in A. MV Capital Management Inc. boosted its stake in shares of Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the period. VisionPoint Advisory Group LLC bought a new position in shares of Agilent Technologies during the 4th quarter worth approximately $29,000. Baystate Wealth Management LLC boosted its stake in shares of Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after acquiring an additional 133 shares during the period. Rosenberg Matthew Hamilton lifted its holdings in Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in Agilent Technologies in the 4th quarter valued at $39,000.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, SVP Philip Binns sold 2,827 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the sale, the senior vice president now owns 9,997 shares of the company’s stock, valued at $1,474,957.38. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on A. JPMorgan Chase & Co. reduced their price target on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Jefferies Financial Group restated a “hold” rating and issued a $135.00 price target (down from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Stifel Nicolaus reduced their price target on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating for the company in a research note on Thursday, May 30th. UBS Group reduced their price target on Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. Finally, Barclays reduced their price target on Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and an average target price of $136.50.

Read Our Latest Report on A

Agilent Technologies Price Performance

Shares of A stock opened at $133.07 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $155.35. The company has a market cap of $38.82 billion, a P/E ratio of 31.46, a P/E/G ratio of 4.51 and a beta of 1.07. The business has a fifty day simple moving average of $141.86 and a 200 day simple moving average of $138.06.

Agilent Technologies (NYSE:AGet Free Report) last announced its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the company earned $1.27 EPS. Agilent Technologies’s revenue for the quarter was down 8.4% on a year-over-year basis. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.25 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be issued a $0.236 dividend. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a yield of 0.71%. Agilent Technologies’s payout ratio is presently 22.22%.

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Further Reading

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.